CMND Stock Forecast: Clearmind Medicine, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$2.63
−13.48% on the day

Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 6 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$1.5M
Ticker Nerd rank
6/ 100
Median analyst target
—
Analysts covering
—
Revenue$0.0
Operating income−$2.2M
Net income−$907K
Free cash flow−$2.7M
Quarterly, 8 quarters to 31 July 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−41.9%
1M
−57.0%
YTD
−98.2%
1Y
−99.6%
From 52W high
−99.6%
From 52W low
0.0%
$3
$637
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Clearmind Medicine, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
6/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
35
Volatility
25
Growth
23
Revisions
20
Accruals
17
Momentum
12
Value
7
Issuance
4

Quality (35): The business earns solid, repeatable profits on what it owns.

Issuance (4): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

CMND stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CMND, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$200$400$600Jan 26Apr 26Jul 26Oct 26CMND

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

CMND appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

CMND vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Clearmind Medicine, Inc. returned −99.6% against +6.9% for the S&P 500, dividends included.

CMND vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26CMNDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CMND analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
0.1×

Cheaper than 97% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−107.0%

Higher than 13% of US stocks

Return on assets
−53.1%

Higher than 7% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Clearmind Medicine, Inc. has a market value of $1.5M.

  • Revenue in the twelve months to 31 July 2026: $0.0.

  • Net income over the same four quarters: −$7.5M.

  • Free cash flow in the twelve months to 31 July 2026: −$7.8M.

  • Shares outstanding: 1.5M.

Statement figures: company filings via Twelve Data, four quarters to 31 July 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

CMND and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CMNDClearmind Medicine, Inc.$1.5M6
ELABPMGC Holdings, Inc.$1.3M3
ARTLArtelo Biosciences, Inc.$1.3M24
APVOAptevo Therapeutics, Inc.$1.4M29
BRTXBioRestorative Therapies, Inc.$1.4M6
ENLVEnlivex Ltd.$1.6M4
JUNSJupiter Neurosciences, Inc.$1.6M14

Take a look at CMND’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Clearmind Medicine, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about CMND

How does Ticker Nerd's model rank CMND?

As at 21 Nov 2026, Clearmind Medicine, Inc. ranks 6 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Quality (35 of 100).

What is the CMND stock forecast for 2030?

No analyst covering Clearmind Medicine, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CMND are extrapolating price history, which says nothing about the business.

How has CMND stock performed over the past year?

Clearmind Medicine, Inc. returned -99.6% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Clearmind Medicine, Inc. do?

Clearmind Medicine Inc. Common Shares represents equity in Clearmind Medicine Inc., a clinical-stage biotechnology company focused on developing novel psychedelic-derived therapeutics and neuroplastogen-based compounds for underserved health conditions. The company’s current work centers on researching and advancing treatments for alcohol use disorder and related behavioral health indications, using proprietary small-molecule drug candidates designed to target underlying neurobiological pathways.

Company

About Clearmind Medicine, Inc.

Clearmind Medicine Inc. Common Shares represents equity in Clearmind Medicine Inc., a clinical-stage biotechnology company focused on developing novel psychedelic-derived therapeutics and neuroplastogen-based compounds for underserved health conditions. The company’s current work centers on researching and advancing treatments for alcohol use disorder and related behavioral health indications, using proprietary small-molecule drug candidates designed to target underlying neurobiological pathways. Clearmind Medicine also operates consumer-oriented and research-driven programs tied to its therapeutic platform, reflecting a broader approach that combines pharmaceutical development with adjacent product concepts. Based in Vancouver, Canada, with active research and development activities in Israel, Clearmind Medicine participates in the life sciences market through a specialized pipeline aimed at regulated medicine development. Its common shares are used by investors to gain exposure to the company’s ongoing biotech research, clinical programs, and intellectual property-driven business model.

Canada · https://www.clearmindmedicine.com